Form 4: Stuart Sloan Acquires Shares in Cero Therapeutics Holdings

Stuart Sloan, a director of Cero Therapeutics Holdings, acquired 532,486 shares of common stock at an average price of $0.1043 per share.

Summary

• Stuart Sloan, a director of Cero Therapeutics Holdings, purchased 532,486 shares of the company's common stock.
• The shares were acquired at an average price of $0.1043 per share.
• Following the transaction, Mr. Sloan beneficially owns 21,067,956 shares indirectly through the SMS Revocable Trust.
• The transaction took place on September 25, 2024.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing of an insider share purchase. It is neither particularly positive nor negative, but the purchase could be interpreted as a sign of confidence.

Positives

• The purchase of shares by a director may indicate confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common when company insiders trade shares. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The reporting of insider transactions is a common requirement to ensure transparency and prevent insider trading.
• The level of detail provided in this filing is consistent with other similar filings.

Stakeholder Impact

• The share purchase may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Cero Therapeutics Holdings, Stuart Sloan, share acquisition, insider trading, beneficial ownership, SMS Revocable Trust